A leading medical device company, Coloplast has received approval from The Center for Devices and Radiological Health (CDRH) of the US Food and Drug Administration (FDA) for changes in labeling of the ...
Coloplast delivered Q4 organic growth of 8% and an EBIT margin1 of 26%, which was negatively impacted by extraordinary costs and currencies. Reported revenue in DKK grew 12% with 3%-pts contribution ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback